Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-celloriginated protein kinase

• In: Poster Presentation
• At: Stockholm (Sweden) (2017)
• Type: Poster
• Poster code: P-A-056-Tuesday
• By: LI, Hua (Wuhan, China)
• Co-author(s): Mengzhu Zheng: School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  Suyu Gao: Wuya College of Innovation，School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China
  Shanshan Luan : School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  Lixia Chen: Wuya College of Innovation，School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China
  Hua Li: School of Pharmacy, Tongji Medical College , Huazhong University of Science and Technology, Wuhan, China
  
• Abstract:

  Backgrounds

  T-cell-originated protein kinase (TOPK) is highly expressed in several cancer cells and promotes tumorigenesis and progression, and therefore, it is an important target for drug treatment of tumor.

  Aims

   Discovery of a TOPK selective inhibitor which can suppress the growth of cancer cells.

  Methods

  A series of methods were used, including in
  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login